Indication of Hepatectomy for Cirrhotic Patients with Hepatocellular Carcinoma Classified as Child-Pugh Class B

被引:0
|
作者
Hideki Nakahara
Toshiyuki Itamoto
Koji Katayama
Hideki Ohdan
Hiroshi Hino
Makoto Ochi
Hirotaka Tashiro
Toshimasa Asahara
机构
[1] Graduate School of Biomedical Sciences,Department of Surgery, Division of Frontier Medical Science, Programs for Biomedical Research
[2] Hiroshima University,undefined
来源
World Journal of Surgery | 2005年 / 29卷
关键词
Orthotopic Liver Transplantation; Partial Hepatectomy; Esophageal Varix; Transcatheter Arterial Embolization; Percutaneous Ethanol Injection;
D O I
暂无
中图分类号
学科分类号
摘要
We clarified the indication of partial hepatectomy in hepatocellular carcinoma (HCC) patients with liver cirrhosis classified as Child-Pugh class B. Univariate analysis revealed that adverse prognostic factors were (1) the presence of ascites, (2) elevated total bilirubin (1.5 mg/dl or higher), (3) reduced choline esterase (160 IU/ or lower), (4) elevated alpha-fetoprotein (AFP) (400 ng/ml or higher), (5) microscopic vascular invasion, and (6) non-curative hepatectomy. Microvascular invasion was excluded in the multivariate analysis because this factor could not be predicted before hepatectomy. Multivariate analysis revealed that independent adverse prognostic factors were (1) elevated total bilirubin (1.5 mg/dl or higher), (2) presence of ascites, (3) elevated AFP (400 ng/ml or higher), and (4) non-curative hepatectomy. The overall 5-year survival rate of patients with none of or only one of the four adverse prognostic factors was 45.8%. The overall 5-year survival rate of patients with two or more adverse prognostic factors was only 7.0%. Partial hepatectomy is the first choice of treatment for patients with none of or only one of the four adverse prognostic factors, whereas orthotopic liver transplantation or other conservative treatment should be considered for patients with two or more adverse prognostic factors.
引用
收藏
页码:734 / 738
页数:4
相关论文
共 50 条
  • [1] Indication of hepatectomy for cirrhotic patients with hepatocellular carcinoma classified as Child-Pugh class B
    Nakahara, H
    Itamoto, T
    Katayama, K
    Ohdan, H
    Hino, H
    Ochi, M
    Tashiro, H
    Asahara, T
    WORLD JOURNAL OF SURGERY, 2005, 29 (06) : 734 - 738
  • [2] Selection Criteria for Hepatectomy in Patients with Hepatocellular Carcinoma Classified as Child-Pugh Class B
    Kuroda, Shintaro
    Tashiro, Hirotaka
    Kobayashi, Tsuyoshi
    Oshita, Akihiko
    Amano, Hironobu
    Ohdan, Hideki
    WORLD JOURNAL OF SURGERY, 2011, 35 (04) : 834 - 841
  • [3] Selection Criteria for Hepatectomy in Patients with Hepatocellular Carcinoma Classified as Child-Pugh Class B
    Shintaro Kuroda
    Hirotaka Tashiro
    Tsuyoshi Kobayashi
    Akihiko Oshita
    Hironobu Amano
    Hideki Ohdan
    World Journal of Surgery, 2011, 35 : 834 - 841
  • [4] Blood Transfusion is Associated with Recurrence of Hepatocellular Carcinoma After Hepatectomy in Child-Pugh Class A Patients
    Harada, Noboru
    Shirabe, Ken
    Maeda, Takashi
    Kayashima, Hiroto
    Ishida, Teruyoshi
    Maehara, Yoshihiko
    WORLD JOURNAL OF SURGERY, 2015, 39 (04) : 1044 - 1051
  • [5] Treatment of hepatocellular carcinoma in Child-Pugh B patients
    Piscaglia, Fabio
    Terzi, Eleonora
    Cucchetti, Alessandro
    Trimarchi, Chiara
    Granito, Alessandro
    Leoni, Simona
    Marinelli, Sara
    Pini, Patrizia
    Bolondi, Luigi
    DIGESTIVE AND LIVER DISEASE, 2013, 45 (10) : 852 - 858
  • [6] Is hepatic resection absolutely contraindicated for hepatocellular carcinoma in Child-Pugh class C cirrhotic patients?
    Wu, CC
    Ho, WL
    Lin, MC
    Tang, JS
    Yeh, DC
    Liu, TJ
    P'eng, FK
    HEPATO-GASTROENTEROLOGY, 1999, 46 (26) : 635 - 639
  • [7] Stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma with Child-Pugh class B
    Cardenes, Higinia Rosa
    Lasley, Foster D.
    Kwo, Paul
    Perkins, Susan M.
    Maluccio, Mary A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma
    Mok, Kevin
    Chen, Olivia
    Yau, Johnny
    Chan, Landon L.
    Chan, Stephen L.
    EXPERT OPINION ON EMERGING DRUGS, 2025, 30 (01) : 1 - 5
  • [9] Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
    Pressiani, T.
    Boni, C.
    Rimassa, L.
    Labianca, R.
    Fagiuoli, S.
    Salvagni, S.
    Ferrari, D.
    Cortesi, E.
    Porta, C.
    Mucciarini, C.
    Latini, L.
    Carnaghi, C.
    Banzi, M.
    Fanello, S.
    De Giorgio, M.
    Lutman, F. R.
    Torzilli, G.
    Tommasini, M. A.
    Ceriani, R.
    Covini, G.
    Tronconi, M. C.
    Giordano, L.
    Locopo, N.
    Naimo, S.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2013, 24 (02) : 406 - 411
  • [10] Impact of the revised Japanese indication criteria for deceased donor liver transplantation on liver cirrhotic patients of Child-Pugh classification B with hepatocellular carcinoma
    Seki, Akihiro
    Yamashita, Tatsuya
    Terashima, Takeshi
    Nakanuma, Shinichi
    Okazaki, Mitsuyoshi
    Kido, Hidenori
    Nishitani, Masaki
    Miyazawa, Masaki
    Takata, Noboru
    Hayashi, Tomoyuki
    Nakagawa, Hidetoshi
    Horii, Rika
    Nio, Kouki
    Yamada, Shinya
    Takatori, Hajime
    Shimakami, Tetsuro
    Honda, Masao
    Yagi, Shintaro
    Yamashita, Taro
    HEPATOLOGY RESEARCH, 2025,